Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 Combination Therapy in Advanced NSCLC
NCT06092268Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06092268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092268.